<< Back Additional Resources WATCH "Understanding Alpha & the Evolving PRRT Landscape" with Dr. Udhayvir Singh Grewal https://www.youtube.com/watch?v=_dE7__jhf9I Download Presentation Slides >>> "2024 Updates on Clinical Trials in Neuroendocrine Tumors" with Dr. Heloisa Soares - April 25, 2024 - LACNETS Patient Educational Event https://www.youtube.com/watch?v=Cdk8uoqKWe0 "Navigating Clinical Trials: Expectations vs Realities" with Taymeyah Al-Toubah, MPH - August 2023 LACNETS Patient Educational Event https://www.youtube.com/watch?v=CXW71vedhIw "The Latest in NET Clinical Trials" - 2023 LACNETS Patient Education Conference https://www.youtube.com/watch?v=h0MFa7jcR4k "Clinical Trials: Why, What & How" - 2023 LACNETS Patient Education Conference https://www.youtube.com/watch?v=Kf3p_j5tFVU "Patient Story & Understanding Clinical Trial Terminology" - 2020 LACNETS Symposium https://www.youtube.com/watch?v=B7XStrrQ6TI "Update on NET Clinical Trials" with Dr. Heloisa Soares - March 2023 LACNETS Educational Event https://www.youtube.com/watch?v=HHtDAQzDj9E "How Clinical Practice Has Been Changed by Clinical Trials in the Last 10 Years" by Dr. Enrique Grande (Credit: INCA) https://www.youtube.com/watch?v=lFyrU7idFUA In this 2022 recording for INCA, Dr. Enrique Grande, MD, PhD, MSc, gives a snapshot of NET research, how clinical trials inform clinical practice, and highlights key trials. "Practice Changing Research in NETS" by Prof. Jonathan R. Strosberg, President of NANETS (Credit: INCA) https://www.youtube.com/watch?v=wWdJfxX5eDs In this 2022 recording for INCA, Prof. Strosberg discusses the current NET clinical trials. "What is the Role of Patients in Trial Design and Efficacy" by Prof. Michael Michael (Credit: INCA) https://www.youtube.com/watch?v=JM1K7ZnXlCo In this 2022 recording for INCA, Prof. Michael discusses the gaps in current NET research and the role of patients in clinical trials design. LISTEN Visit the podcast episode page for more resources >>> Visit the podcast episode page for more resources >>> READ "Why Participate in Clinical Trials?" Clinical Trials Glossary "How to Prepare for Clinical Trials" Info Sheet Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event

<< Go back to the Podcast page EPISODE 53 - Spotlight on Surgical Oncology Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this episode, surgical oncologist Dr. Seth Concors of Emory’s Winship Cancer Institute discusses the role of the surgical oncologist within the multidisciplinary care team for neuroendocrine cancer. We explore what surgical oncologists do, why NET-specific experience matters, how surgical decisions are made, and what patients can expect during a surgical consultation. The conversation highlights coordination across care teams, common patient concerns, and the importance of informed decision-making and second opinions, offering practical guidance for patients and caregivers navigating surgical care in neuroendocrine cancer. TOP TEN QUESTIONS Understanding the Surgeon’s Role Who is a surgical oncologist, and what kind of training does that involve? How is a surgical oncologist similar to—or different from—other types of surgeons? Patients may hear the term “HPB surgeon.” What does that mean, and how can a patient tell if their surgeon is an HPB surgeon? When a patient is looking for a surgeon, how can they find someone who is the “right fit” for them? How can patients know whether a surgeon has experience with the specific operation they may need—such as a Whipple procedure, liver surgery, or lung surgery? How important is it for a surgeon to be familiar with neuroendocrine tumors specifically? What should patients expect at their first appointment with a surgical oncologist? What key information are you usually trying to communicate during that first visit? What questions do you encourage patients and caregivers to ask their surgeon? How often should patients expect to see their surgical oncologist, and at what points in their care? Surgical Decision-Making How do you determine whether someone is a surgical candidate? What is the typical goal of surgery for neuroendocrine tumors? If someone is not a surgical candidate initially, does that mean surgery is off the table forever? Are there treatments that can help make surgery possible in the future? How many NET surgeries can someone safely have over their lifetime? Can major surgeries—such as extensive liver resections—affect eligibility for future treatment options? Multidisciplinary and Coordinated Care How do surgical oncologists work within a multidisciplinary care team for NET patients?How do you collaborate with providers at different institutions, such as a local oncologist working with a NET specialty center? What is your perspective on second opinions, specifically for neuroendocrine cancer? Many patients worry about carcinoid crisis during surgery. How do you address and manage those concerns? Preparing for Surgery Patients often ask how they can best prepare—physically and emotionally—for surgery. What guidance do you typically offer? BONUS: What research is currently being done involving neuroendocrine surgery? MEET DR. SETH J. CONCORS Seth J. Concors, MD Surgical Oncologist Winship Cancer Institute Emory University Seth Concors, MD is an academic surgical oncologist at Emory University and the Winship Cancer Institute, where he serves as Associate Program Director for both the General Surgery Residency and the Complex General Surgical Oncology Fellowship, and Director of the Surgical Oncology Research Fellowship. He leads Emory’s Peritoneal Surface Malignancy and Neuroendocrine Tumor surgical programs, with clinical and research interests focused on gastrointestinal neuroendocrine tumors, cytoreductive surgery/HIPEC, and survivorship outcomes. Dr. Concors is actively involved in national surgical societies including SSO, SSAT, NANETS, ACS, and ECOG-ACRIN, and his work emphasizes multidisciplinary collaboration, prospective outcomes research, and surgical education. He is committed to advancing patient-centered cancer care while mentoring the next generation of surgical oncologists. RESOURCES QUESTIONS FOR THE CARE TEAM In this podcast episode, Dr. Concors shares questions that are both appropriate and encouraged for patients and caregivers to ask their care team. Provider Experience & Expertise What is your level of familiarity with neuroendocrine tumors? How engaged are you in this field, including research and ongoing work? How familiar are you with managing patients who have had multiple prior operations? Patient Volume How many patients with neuroendocrine tumors do you take care of in a given year? Procedure-Specific Experience How much experience do you have performing this operation? How many times have you done this operation? How familiar are you with the complications of this operation? Institutional Experience How commonly is this operation performed at this hospital or cancer center? Questions for Your Anesthesiologist What is your expertise in taking care of patients with neuroendocrine tumors who are undergoing surgery? What is your experience managing changes in blood pressure while I am under anesthesia? What strategies will you use to monitor my heart and lungs during surgery? CLINICAL TRIALS Clinical trials mentioned in this podcast episode: SWOG 2104: Adjuvant CAPTEM for pancreatic NET SWOG 2408: Lanreotide vs Placebo Before Surgery to Prevent Pancreatic Fistula Explore the NCF Surgery Resources DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

LUNCHEON WITH THE EXPERTS “Luncheon With The Experts” is a recurring educational opportunity (previously hosted by the Carcinoid Cancer Foundation) that connects patients and caregivers with extraordinary experts in neuroendocrine cancer. The sessions are hosted by Rain Bennett. This program gives the unique opportunity for neuroendocrine specialists — like oncologists, surgeons, interventional radiologists, gastroenterologists, endocrinologists, etc. to answer and address broad-based questions from patients and caregivers globally via live chat. Programs are typically delivered live (over Facebook Live and YouTube Live) at noon Eastern Time, allowing participants to join during their lunch break. Live sessions are recorded and will be available after the live event. Upcoming Episodes "Luncheon With The Experts" With Dr. Mintallah Haider October 22, 2026, Noon - 1 PM Eastern (9 AM Pacific) “Luncheon With The Experts” is a recurring educational opportunity (previously hosted by the Carcinoid Cancer Foundation) that connects patients and caregivers with extraordinary experts in neuroendocrine cancer. The sessions are hosted by Rain Bennett. Join on October 22nd and drop your questions for Dr. Haider to answer in the comments on Facebook or chat on YouTube. Join Recent Episodes Dr. Aman Chauhan Sep 17, 2026 Aman Chauhan, MD, MBBS, is an Associate Professor of Medicine at the University of California, San Francisco, specializing in neuroendocrine cancers. He completed his oncology fellowship at the University of Kentucky and an NCI externship focused on clinical trial design. His clinical and research interests include neuroendocrine tumors and carcinomas, radiopharmaceutical therapy, theranostics, treatment sequencing, symptom management, and clinical trials. Dr. Chauhan has published extensively, served on AJCC and ASCO neuroendocrine tumor guideline committees, and is an active member of NANETS. He is board certified in internal medicine and medical oncology. Visit the Event Page Dr. J. Randolph "Randy" Hecht Aug 27, 2026 J. Randolph “Randy” Hecht, MD, is a Professor of Clinical Medicine at UCLA and Medical Director of the UCLA GI Neuroendocrine Tumor Program. He is an internationally recognized gastrointestinal oncology researcher with expertise in neuroendocrine tumors, clinical trials, targeted therapies, immunotherapy, CAR-T, and radiopharmaceutical therapies. Dr. Hecht also serves on the Neuroendocrine Cancer Foundation Medical Advisory Council. Visit the Event Page Dr. Jonathan Strosberg July 23, 2026 Jonathan Strosberg, MD, is a professor of gastrointestinal oncology and section head of the Neuroendocrine Tumor Division at Moffitt Cancer Center. He specializes in neuroendocrine malignancies and has published extensively on their diagnosis and management, including in The New England Journal of Medicine, Journal of Clinical Oncology, and The Lancet Oncology. He is a past president of NANETS and serves on the NCCN Neuroendocrine Guidelines Committee. Visit the Event Page Dr. Jason Starr May 28, 2026 Jason S. Starr, DO, is a hematologist/oncologist at Mayo Clinic Comprehensive Cancer Center. He specializes in gastrointestinal malignancies, with a special interest in neuroendocrine tumors, clinical research, and clinical trial development. He is board certified in internal medicine, hematology, and oncology. Visit the Event Page Dr. Jaydira Del Rivero Apr 30, 2026 Jaydira Del Rivero, MD, is an endocrinologist and medical oncologist at the National Institutes of Health. She is a physician scientist in the Developmental Therapeutics Branch, where her work focuses on neuroendocrine neoplasms, endocrine malignancies, clinical trials, and targeted therapies for gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer, pheochromocytoma, and paraganglioma. Visit the Event Page Dr. Boris G. Naraev March 26, 2026 Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute, specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate Professor of Medicine at the Division of Hematology and Medical Oncology of the University of South Florida, Morsani College of Medicine. Visit the Event Page Dr. Udhayvir Grewal January 22, 2026 Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team.

Our 2025 NCF Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET or neuroendocrine tumor) patients and caregivers to deepen your understanding of NETs. 2025 Neuroendocrine Cancer Foundation's Annual Patient Conference Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing 11:48 Play Video 1. Welcome & Introductions • Neuroendocrine Cancer Foundation Team Now Playing 16:22 Play Video 2. What is Neuroendocrine Cancer? • Bhavana Konda, MD, MPH • Neuroendocrine Cancer Foundation Now Playing 17:33 Play Video 3. What Matters About Biomarkers & Blood Tests • Thorvardur Halfdanarson, MD • @NCFCancer Agenda Sponsors Speaker Bios Spanish Resources Watch the 2024 Conference Watch the 2023 Conference ABOUT THE CONFERENCE Our 2025 virtual annual patient conference is designed for neuroendocrine cancer (NET or neuroendocrine tumor) patients and caregivers to help you identify aspects and factors that matter most about managing your disease. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to watch this virtual conference. Learn from top neuroendocrine cancer experts from across North America, honing in on what matters-- from blood tests to clinical trials. Our experts cover the basics of Neuroendocrine Cancer, imaging, symptom management, surgery, PRRT and systemic treatments. Our speakers focus on what you need to know about that topic to help you understand your disease and next treatment options. Gain insight on what matters most in determining recommendations from expert panel discussions. Hear NET journeys from those living with Neuroendocrine Cancer. Q&A at the end of the conference presentations. Watching virtually allows you to pause, rewind and replay. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> Agenda AGENDA SPANISH RESOURCES Spanish ¿Qué importa sobre: las terapias dirigidas al hígado? Dr. Alejandro Gabutti 2025 NCF Conference Lo Importante de PRRT: ¿Qué es PRRT y Cómo Funciona? Cecilia Carreras Velázquez, MD Medicina Nuclear Hospital Ángeles Lomas 2025 NCF Conference Click here for more Spanish resources >>> THANKS TO OUR SUPPORTERS Sponsors The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of the Neuroendocrine Cancer Foundation.

Learn about somatostatin analog therapies for neuroendocrine tumors, including SSA treatment resources, injections, patient assistance and expert education. Somatostatin Analog (SSA) Therapy for Neuroendocrine Tumors READ CLICK HERE FOR AN EXCELLENT SUMMARY OF SSA'S BYNFEZIA PEN™ (OCTREOTIDE ACETATE) INJECTION COPAY ASSISTANCE - BYNFEZIA PEN™ (OCTREOTIDE ACETATE) Read 'Practical Tips for Patients on "The Shot" LISTEN Podcast Episode 32: Focus on Somatostatin Analogues (SSAs)

Find support and resources for children affected by a parent's cancer, including counseling, support programs, anxiety resources and grief support. Support & Resources for Children Affected by Cancer CancerCare for Kids® provides free, professional support services for parents, children, and adolescents affected by cancer, as well as information about helping children understand cancer and additional resources. Help with Hope is a support group to the children whose parent has cancer. If you are a parent with cancer and have a child between the ages of 8 and 17, they can attend an online meditation support group with other kids who understand what they are going through, parents are also invited! Kesem is committed to creating a world where every child who has a parent with a cancer diagnosis or has lost a parent to cancer is never alone. Kesem supports these children through and beyond their parent’s cancer with free, fun-filled creative programs and a lasting community. Lynn Lyons helps families navigate through fear and anxiety. GRIEF RESOURCES FOR CHILDREN Child Life Services at City of Hope – addresses the needs of infants, children, teens, and families during hospitalization and outpatient treatment. Our House Grief Support – provides children with grief support services, education, resources, and hope. Comfort Zone – offers a two-day camp for grieving kids. Inner Harbor – offers mental health support for grieving students. They also train high school and college teachers and counselors and even Greek houses to support young adults. High Mark Caring Place – manages the Children's Grief Awareness Day page, helping to remind us that grieving kids need our love. Click here for Caregiver Resources SPREADING AWARENESS Designer: Lauren Buntin Download

The Giovanna Joyce Imbesi Above & Beyond Award The Giovanna Joyce Imbesi Above & Beyond Award is given to individuals in recognition of outstanding dedication to NET patient advocacy. Recipients of this award demonstrate an attitude of excellence, awareness, and hope for the neuroendocrine cancer community. The award is in honor of the late founder of LACNETS (now Neuroendocrine Cancer Foundation), Giovanna Joyce Imbesi . 2025 Awardee DUSTY HURLEY Watch the award presentation 2024 Awardee VAL TIPPY Watch the award presentation 2023 Awardee TOM BAJORAS Watch the award presentation 2022 Awardee MICHEL DEQUEVEDO Watch the award presentation 2021 Awardee SAMUEL PRENTICE JR. Watch the award presentation 2020 Awardee MARY DONLEVY Watch the award presentaion 2019 Awardee BRENT CURRIE Watch the award presentation 2018 Awardee BETH DEBLASE Watch the award presentation

Wellness Coaching Interest Form This coaching is about wellness coaching and self-care. It does not involve navigation or NET-specific discussions. For NET-specific information and resources, visit our Resources Page . For NET support assistance, go to our Support Line .

Symptom Management < Back to Topics Play Video Play Video 01:24:02 Practical Tips in Managing Neuroendocrine Cancer Care • • Sep 29, 2026 ABOUT Join Taymeyah and Tiffany as they share important insights to help you spearhead your medical team and confidently navigate your healthcare. Gain practical logistics for managing the ongoing cycle of scans, lab work, and "ologist" appointments. Discover well-informed, real-world suggestions on finding and building strong partnerships with your providers and specialists. We hope this discussion empowers you to effectively and efficiently coordinate your care. Visit the event page at https://www.ncf.net/events/sep2026 Play Video Play Video 01:09:03 Episode 49: "Understanding Carcinoid Syndrome & GLP-1 Drugs in Neuroendocrine Tumors" - Dr. Dillon ABOUT THIS EPISODE Carcinoid syndrome can be confusing and often difficult to diagnose. In this episode, Dr. Joseph Dillon, Endocrinologist and Director of the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic, explains what carcinoid syndrome is, how it’s diagnosed, and the various ways it can be treated. He highlights key symptoms, testing, and treatment approaches—including somatostatin analogs and telotristat—and discusses how to distinguish carcinoid syndrome from other causes of diarrhea and flushing. In the second half of the episode, Dr. Dillon shares insights from his separate line of research on GLP-1 receptor agonist weight-loss drugs (such as Ozempic® and Mounjaro®) and their potential implications for neuroendocrine tumor patients. (Note: this topic is unrelated to carcinoid syndrome.) MEET DR. JOSEPH DILLON Dr. Dillon is a Professor of Medicine in the Division of Endocrinology at the University of Iowa Hospitals and Clinics. He directs the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic. This was the first and only US NET Clinic to be recognized as a Center of Excellence by the European NET Society. He is also the Director of the PheoPara Alliance Center of Excellence at University of Iowa. His clinical practice is entirely focused on the care of people with neuroendocrine tumors, both carcinoid type and paraganglioma. He has participated in clinical trials and publications related to diagnostic and therapeutic nuclear agents and drug therapies in this population. Prior to focusing on NET he made important discoveries in the field of GLP-1 which are now becoming of importance to NET patients taking popular weight loss drugs. TOP TEN QUESTIONS: 1. What is carcinoid syndrome? 2. Who is affected by carcinoid syndrome? How does someone know if they have carcinoid syndrome? 3. What are the tests for carcinoid syndrome? How is carcinoid syndrome distinguished from other causes of my symptoms? *Could the tests be negative but someone still have carcinoid syndrome? 4. Can someone have no evidence of neuroendocrine tumors and still have carcinoid syndrome? 5. For those who have carcinoid syndrome, what additional tests should they have? 6. Why should carcinoid syndrome be treated? What are the possible issues if it is not treated? 7. How is carcinoid syndrome treated? *What is on the horizon for carcinoid syndrome treatment? 8. Can carcinoid syndrome be prevented or detected early? 9. Is there anything people can do to prevent or lessen carcinoid syndrome symptoms? Are there any factors that worsen carcinoid syndrome such as age, weight or other diseases? 10. You recently published a study discussing possible risks of using certain weight loss drugs in people with neuroendocrine cancer. Could you tell us more about this study? What was the drug and what did you find? What does it mean? What do you want the NET patient community to understand about your recent findings? Visit https://www.ncf.net/podcast/49 for more information. Play Video Play Video 01:01:43 Episode 20 - Gastric NET, Gastrinomas & Zollinger-Ellison Syndrome (ZES) ABOUT THIS EPISODE Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. MEET THE SPEAKER David C. Metz, MD Professor of Medicine, Perelman School of Medicine Co-Director Emeritus, University of Pennsylvania Neuroendocrine Tumor Program After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. TOP 10 QUESTIONS 1. What is Gastric NET? How is it found? What are the symptoms? How does it differ from “stomach cancer” or other types of NETs? 2. How is Gastric NET treated and how is it monitored? 3. What is a Gastrinoma? How and where is it found? Are Gastrinomas and Gastric NET the same thing? 4. How is a Gastrinoma treated? 5. How is a Gastrinoma monitored? - How often do you recommend Endoscopies or Gastrin level lab testing? - Does a high Gastrin level mean someone has a Gastrinoma or are there other causes? Can you have a high Gastrin level without having a gastrinoma? 6. What is Zollinger-Ellison Syndrome? How is it found? What are the common symptoms from ZES/functioning Gastrinomas? 7. How is Zollinger-Ellison Syndrome treated? How is Zollinger-Ellison Syndrome monitored? Does ZES put you at risk for other conditions/complications? 8. What is a common Proton Pump Inhibitor dose for someone with ZES? Is there a danger in taking PPIs for a long time or in high doses? 9. I’ve been told I have an ulcer? Am I at risk for cancer? 10. What are advances for gastric nets, gastrinomas or Z-E syndrome that we should be aware of or excited about? *Bonus question: What last words of hope would you like to leave the NET community with? For more resources and the transcript of this episode, visit https://www.lacnets.org/podcast20. Play Video Play Video 17:59 5. What Matters About Symptom Management • Vineeth Sukrithan, MD • Neuroendocrine Cancer Foundation "What Matters About Symptom Management" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Vineeth Sukrithan, MD Medical Oncologist Ohio State University Play Video Play Video 01:29:43 When Hormones Interfere With Quality of Life • Dr. Jaydira Del Rivero • NCF 2026 When hormones are out of balance, the symptoms can have a significant impact on quality of life for people living with neuroendocrine cancer. In this Neuroendocrine Cancer Foundation (NCF) educational webinar, Dr. Jaydira Del Rivero, medical oncologist at the National Cancer Institute, explores how hormone excess, hormone deficiencies, and cancer treatments can affect the endocrine system—and what patients and caregivers should know. Topics covered include: • How hormone excess and hormone deficiency can affect the body • Hormone-related symptoms associated with neuroendocrine tumors • Carcinoid syndrome vs. serotonin syndrome • How immunotherapy may affect the pituitary, thyroid, adrenal glands, and pancreas • Adrenal insufficiency and cortisol deficiency • Thyroid dysfunction associated with cancer therapies • Endocrine effects of tyrosine kinase inhibitors (TKIs) and somatostatin analogs • Changes in blood glucose and insulin production • Sex hormone changes during treatment • Flushing related to carcinoid syndrome and menopause • GLP-1 agonists in the setting of neuroendocrine tumors • Symptoms and patterns patients should discuss with their healthcare team • Warning signs that may require urgent medical attention The goal of this session is to help patients and caregivers recognize symptoms earlier, understand when hormone testing may be appropriate, and have more informed conversations with their oncology and endocrinology teams. This webinar is for educational purposes only and is not a substitute for medical advice. Please contact your healthcare team with questions about your individual diagnosis, symptoms, or treatment. Learn more about the Neuroendocrine Cancer Foundation and its educational and support resources through NCF. Visit the event page at https://www.ncf.net/events/aug2026. Play Video Play Video 20:32 13. Navigating Treatment Side Effects • Jason Starr, DO • Mayo Clinic • 2026 NCF Conference In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jason Starr, medical oncologist at Mayo Clinic in Jacksonville, Florida, presents “Navigating Treatment Side Effects.” Dr. Starr discusses how patients and care teams can balance treatment effectiveness with quality of life when using therapies for neuroendocrine cancers. He emphasizes the importance of early communication with the medical team, recognizing side effects promptly, holding medication when appropriate, using acute care resources when needed, and adjusting doses to find the right balance for each patient. This presentation reviews potential side effects and management strategies for somatostatin analogs, Lutetium-177 dotatate/Lutathera, PRRT, everolimus/Afinitor, CAPTEM, capecitabine, temozolomide, and tyrosine kinase inhibitors such as sunitinib and cabozantinib. Topics include fatigue, diarrhea, nausea, injection site pain, exocrine pancreatic insufficiency, blood sugar changes, gallbladder issues, bone marrow suppression, mouth sores, skin rash, blood pressure changes, wound healing concerns, thyroid issues, and medication interactions. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #TreatmentSideEffects #SideEffectManagement #PRRT #Lutathera #CAPTEM #Everolimus #Cabozantinib #SomatostatinAnalogs #MayoClinic #NCF #PatientConference Play Video Play Video 09:44 "Practical Tips For Patients Preparing For Chemotherapy" • Lisa Yen, NP, NBC-HWC NET caregiver Lisa Yen’s “show and tell” of tips, tricks, and items she and her husband found to be helpful when dealing with chemotherapy. Read LACNETS blogpost Practical Tips For Patients Preparing For Chemotherapy: https://www.lacnets.org/post/practical-tips-for-patients-preparing-for-chemotherapy. For more information on LACNETS, visit www.LACNETS.org. Play Video Play Video 06:36 "Practical Tips for Cabozantinib" with Lisa Yen Starting a new cancer treatment can feel overwhelming—but you don’t have to navigate it alone. In this video, Lisa Yen, Director of Programs and Outreach at the Neuroendocrine Cancer Foundation, shares practical tips and real-life insights for patients preparing to take Cabozantinib (Cabometyx). Drawing from both her professional experience and her personal journey supporting her husband with a neuroendocrine tumor, Lisa walks through what to expect, how to prepare, and how to manage common side effects. You’ll learn about: Key resources, including oncology pharmacists and free patient care kits What’s included in the Cabometyx care kit and how it can help Common side effects like nausea, diarrhea, hand-foot syndrome, and high blood pressure Tips for tracking symptoms and staying organized with a treatment journal How and when to take Cabozantinib safely The importance of communication with your healthcare team This video is designed to help reduce uncertainty and empower patients and caregivers with actionable, experience-based guidance. 💡 Whether you’re just starting Cabozantinib or supporting someone who is, these tips can help you feel more prepared and confident in your treatment journey. Disclaimer: Always consult your healthcare team with any questions or concerns about your care. This content is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 18:45 "The Endocrine in Neuroendocrine" • Run Yu, MD, Endocrinologist, UCLA •2024 NET Cancer Day Symposium Dr. Run Yu, Endocrinologist from UCLA, discusses "The Endocrine in Neuroendocrine" at the 2024 NET Cancer Day Symposium. Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. Play Video Play Video 21:13 13. Managing NET Symptoms & Treatment Side Effects (Dr. Sandy Kotiah) - 2022 LACNETS Conference Dr. Sandy Kotiah addresses the management of #NET symptoms and treatment side effects. Speaker: Sandy Kotiah, MD Medical Oncologist, Mercy Medical 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:17 Patient Story: NET Patient shares how she is thriving as a NET patient (LACNETS) NET Patient Cindy shares how she is thriving as a NET patient. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 04:26 Patient Story: NET Patient shares about symptom management (LACNETS) NET Patient Brent shares about symptom management. June 20, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 06:00 11. Patient Story about Symptom Management (Val) - 2021 LACNETS Virtual Conference NET Patient Val shares her experience with symptom management and NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:02:18 LACNETS - "Pain Management for NETs" Dr. Najmeh Sadoughi Dr. Najmeh Sadoughi "Multidisciplinary Approaches to Pain Management for Neuroendocrine Tumors" Najmeh Sadoughi, MD Board Certified Interventional Pain Specialist LACNETS Patient Education Seminar January 9, 2018 UCLA Los Angeles, California LACNETS is a program by Generate Possibility, a 501(c)(3) non-profit corporation. Los Angeles Carcinoid Neuroendocrine Tumor Society www.LACNETS.org Play Video Play Video 01:38:07 LACNETS Webinar: "Management of Diarrhea in NETs” with Dr. Shirley Paski Management of Diarrhea in NETs” with Dr. Shirley Paski Recorded on October 13th, 2020 Speaker: Shirley Paski, MD, IM/Gastroenterology, Cedars-Sinai Medical Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 49:02 Symptom Management: Diarrhea, Hyperglycemia & Diabetes - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:30) Brent, NET Patient "Symptom Management: Diarrhea" (6:30 - 29:05) David C. Metz, MD, Gastroenterology Penn Medicine "Symptom Management: NET-related Hyperglycemia and Diabetes" (29:05 - end of video) Run Yu, MD, PhD , Endocrinology UCLA Health For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:19 12. Symptom Management (Dr. Del Rivero) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Jaydira Del Rivero, MD Endocrinologist, Oncologist NIH This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 45:02 "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" con Dr. Jaydira Del Rivero "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" con Dr. Jaydira Del Rivero Presentadora: Jaydira Del Rivero, MD Endocrinologist, Oncologist; NIH Para obtener más recursos en español, visite www.LACNETS.org/spanish-resources. < Back to Topics Next Topic >

IL13Rα2 CAR T Cell Study for Solid Tumor Cancers << Back Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT04119024 DRUG/TREATMENT : IL13Ralpha2 CAR T Cells PHASE : 1 STATUS : Recruiting at Stanford Medicine, UCLA, and City of Hope SPONSOR : CIRM DESCRIPTION: https://www.youtube.com/watch?v=FgGTrZ6lx1w Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024 This clinical trial investigates a novel gene therapy (IL13Ralpha2 CAR T cells) approach for advanced melanoma and other solid tumors. It aims to assess the safety and effectiveness of gene-modified immune cells targeting cancer cells. The trial seeks to determine the safety and potential effectiveness of IL13Ralpha2 CAR T cells in fighting cancer. By evaluating the dose and the IL13Ralpha2 CAR T cells ability to attack cancer cells, researchers at UCLA, Stanford, and City of Hope aim to improve treatment options for advanced cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Christy Sidhu; UCLA = Jonsson Comprehensive Cancer Center EMAIL: PICICenterResearch@mednet.ucla.edu PHONE: 310-206-5087 Principal Investigators: Dr. Antoni Ribas, MD, PhD (UCLA) Dr. Allison Betof Warner, MD, PhD (Stanford Medicine) Dr. Yan Xing, MD, PhD (City of Hope) RESOURCES : Patient Information Sheet

Newly Diagnosed < Back to Topics Play Video Play Video 17:40 2. Understanding Neuroendocrine Cancer: What Should I Know About My Cancer? • Dr. Udhayvir Grewal In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Udhayvir Grewal, GI and neuroendocrine medical oncologist at Winship Cancer Institute of Emory University, presents “Navigating an Understanding of Neuroendocrine Cancer: What Should I Know About My Cancer?” Dr. Grewal explains key concepts that patients and caregivers should understand after a neuroendocrine cancer diagnosis, including grade, stage, differentiation, Ki-67, mitotic index, imaging, somatostatin receptors, hormone production, molecular profiling, and the importance of a specialized multidisciplinary care team. This presentation also discusses the role of CT, MRI, and PET scans; how imaging can affect staging and treatment planning; why molecular testing may help guide personalized therapy; and why expert care and patient advocacy are essential throughout the neuroendocrine cancer journey. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NETCancer #NeuroendocrineTumors #NETs #CancerEducation #NCF #PatientConference #CancerDiagnosis #CancerTreatment #CancerSupport #ClinicalTrials Play Video Play Video 01:34:59 Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand • 2026 NCF Event • Apr 23, 26 ABOUT Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Join Dr. Osama MoSalem, medical oncologist at St. Luke’s in Kansas City, for a clear and compassionate overview of what every newly diagnosed NET patient should know. Dr. MoSalem explains what neuroendocrine cancer is, why it behaves differently from more common cancers, and how its unique features influence diagnosis and treatment. This session walks you through the most important early concepts, including: - Grade and stage: what they mean and why they matter - Key tests and scans used at diagnosis - Treatment pathways, including when to consider surgery, medications, targeted therapies, radioligand therapy, or clinical trials - Essential questions to ask your care team - Practical first steps to help you feel more prepared and empowered Whether you’re newly diagnosed, supporting a loved one, or simply trying to better understand this disease, this webinar provides a solid foundation to help you make informed decisions with greater clarity and confidence. Visit the event page at https://www.ncf.net/events/apr2026 Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 17:45 04. NETs 101: NET Terms & Concepts You Need to Know • Bassam Sonbol, MD • Arizona • @NCFCancer ⁩ Play Video Play Video 25:45 "NETS 101" • Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium @NCFCancer Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium • Santa Monica, CA Speaker: Jaydira Del Rivero, MD Medical Oncologist Endocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org. Play Video Play Video 35:16 "Understanding NET Diagnosis" with Dr. Chandrasekharan • 2024 #LACNETS Patient Conference 2. "Understanding NET Diagnosis" with #Dr.Chandrasekharan Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 21:51 NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference Watch "NETS 101: Overview of NET Terms & Concepts" with Dr. Aman Chauhan. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit, LACNETS.org. Play Video Play Video 15:22 05. NET Surgery: Making Decisions & Preparing for Surgery (Dr. Clarke) - 2022 LACNETS Conference Dr. Callisia Clarke addresses surgery for neuroendocrine cancer including decision-making & preparing for surgery. Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 07:50 Patient Story: NET Patient shares about the first year of her NET journey (LACNETS) NET Patient Laurie shares about the first year of her NET journey. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:37:42 LACNETS Webinar: "Sequencing of Neuroendocrine Tumor Treatments" with Dr. Eric Liu LACNETS webinar - “Sequencing of Neuroendocrine Tumor Treatments" Friday, May 24th, 2020 SPEAKER: Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist Rocky Mountain Cancer Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 01:04:39 LACNETS - NET VITALS Webinar - September 6th, 2018 Download NET VITALS here: www.lacnets.org/netvitals NET VITALS Webinar - Question Timing Guide: Introductions: Start - 10:25 Q1. My neuroendocrine tumor (NET) was found: 10:41 Q2. I am a neuroendocrine tumor (NET) patient and my primary (origin) tumor is: 11:05 Q3. My NET has spread (metastasized) to: 11:57 Q4. My Ki-67 index is 14:20 Record-keeping: 14:38 Pathology report example: 17:25 Q5. My neuroendocrine tumor is: 18:15 Q6. My neuroendocrine tumor is: 22:17 Q7. I have symptoms: 23:50 Q8. I have had symptoms for ____ years (if applicable). 23:50 Q9. I have had the following types of imaging, and possess the disk and/or report: 29:30 Q10. I have had the following labs, and possess the report (if applicable): Indicate if abnormal. 32:55 Q11. Surgery to remove primary tumor(s): 38:45 Q12. Surgery to remove metastatic tumor(s): 39:05 Q13. Other surgery 39:40 Q14. Liver-Directed treatment: 40:10 Q15. Somatostatin Analogs (SSA) & Others: 42:48 Q16. Chemotherapy / Biologically-Targeted / Immunotherapy, including Clinical Trials/ PRRT (Peptide Receptor Radionuclide Therapy, i.e. Lutathera®): 44:03 Q17. I am diabetic: 47:50 Q18. ALLERGIES (Medications/Food): 48:05 Q19. FAMILY HISTORY (Specify cancer and/or rare diseases): 48:20 Q20. I have had Genetic Testing: 48:37 Q21. MEDICATIONS/SUPPLEMENTS (including vitamins, digestive enzymes): 49:01 Q22. CURRENT PHYSICIAN(S) & MEDICAL TEAM 49:29 Q23. SOCIAL SUPPORT 50:13 Q&A with the NET VITALS Team 52:23 What is NET Vitals? LACNETS created NET VITALS as a quick snapshot of the most important questions for patients and healthcare professionals to know about neuroendocrine cancer. NET VITALS is a 20-question tool designed to highlight the vitals of NET cancer, all in one document. This allows the physician and patient to more easily communicate with all of the basics in one place. Webinar Leaders: Giovanna Joyce Imbesi, MBA, Executive Director, LACNETS Lisa Yen, NP, NBC-HWC, Program Director, LACNETS Dan Li, MD, Medical Oncologist, City of Hope Josh Mailman, MBA, President, NorCal CarciNET Learn more here: https://www.lacnets.org/lacnets-blog/netvitals Play Video Play Video 20:22 "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) Presentadora: Heloisa Soares, MD, PhD Medical Oncologist; Huntsman Cancer Institute Para obtener más recursos en español, visite www.LACNETS.org. Play Video Play Video 30:23 04. What to Expect with a NET Expert Consultation (Dr. Soares) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Heloisa Soares, MD, PhD Medical Oncologist Huntsman Cancer Institute This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 42:50 Finding a NET Expert + Surgery for NETs - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: LACNETS Conference Welcome (0:00 - 5:44) Lindsey Jeu De Vine, Director of Communications, LACNETS Lisa Yen, NBC-HWC, Program Director, LACNETS "Finding a NET Expert" (5:44 - 22:25) Cindy Lovelace , Executive Director Healing NET Foundation "Surgery for NETs" (22:25 - end of video) Alexandra Gangi, MD , Surgical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 43:19 "NETs 101" with Medical Oncologist Dr. Sandy Kotiah of Mercy Medical Medical oncologist and NET expert Dr. Kotiah covers what to expect during your first visit with your medical oncologist – plus labs, scans, and prognosis. Speaker: Sandy D. Kotiah, MD Medical Oncologist, Hematologist Mercy Medical To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >

Diarrhea < Back to Topics Play Video Play Video 19:19 3. Navigating Scans • Dr. Delphine Chen, Fred Hutch Cancer Center • Neuroendocrine Cancer Foundation In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Delphine Chen, nuclear medicine physician at Fred Hutch Cancer Center and the University of Washington, presents “Navigating Scans.” Dr. Chen explains how imaging is used in the diagnosis, staging, monitoring, and treatment planning of neuroendocrine tumors. She discusses commonly used imaging tools, including CT, MRI, and Dotatate PET, and explains why different scans may be recommended depending on the location and biology of the tumor. This presentation covers the role of multiphase contrast CT and MRI in identifying liver metastases, how Dotatate PET can help detect well-differentiated neuroendocrine tumors, and how imaging may be used to assess eligibility for peptide receptor radionuclide therapy (PRRT). Dr. Chen also discusses surveillance imaging, treatment monitoring, scan frequency, and the importance of interpreting imaging results within the context of each patient’s care plan. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #DotatatePET #CancerImaging #CTScan #MRI #PRRT #NCF #PatientConference #CancerEducation Play Video Play Video 14:53 4. What Matters About Scans? • Nadine Mallak, MD • @NCFCancer "What Matters About Scans" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Nadine Mallak, MD Radiologist & Nuclear Medicine Oregon Health & Science University @NCFCancer Play Video Play Video 23:47 "Understanding NET Scans" with Dr. Nadine Mallak • 2024 LACNETS NET Patient Conference 3) Understanding NET Scans • 2024 Neuroendocrine Tumor Patient Conference Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 19:08 The Latest in NET Imaging • Dr. Nadine Mallak • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Imaging" with Dr. Nadine Mallak. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 16:32 10. The Latest in NET Imaging & PRRT (Dr. Thomas Hope) Radiologist Dr. Thomas Hope addresses the latest in NET imaging and PRRT. Speaker: Thomas Hope, MD Radiologist, UCSF 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:33:28 LACNETS Webinar: "NET Imaging: Scans & Reports" with NET Radiologist Dr. Gary Ulaner NET radiologist Dr. Gary Ulaner from Hoag Family Cancer Institute explains different scans used for NET imaging and how to understand your radiology reports. This webinar includes a presentation and live Q&A. Additional NET imaging resources can be found here: lacnets.org/imaging To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >